SCHEMBL968572

SCHEMBL968572

CCCCCCCCCCCCCCCCCC(=O)NCC(O)CO

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.58
ASAH1 Q13510 1/20 0.55
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 1/20 0.51
DUSP3 P51452 1/20 0.51
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.50
HSP90AA1 P07900 1/20 0.50
DNM1 Q05193 1/20 0.49
NAAA Q02083 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13213912 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL14253316 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL9061545 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL26393717 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL11310187 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL24339916 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL5410583 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL1004187 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL22067566 1.00 FAAH (0.58) FAAHASAH1MEN1KMT2AKDM4E
SCHEMBL23799216 0.98 FAAH (0.55) FAAHASAH1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116322759-A Phospholipid compounds and uses thereof 吉利德科学公司 2023-06-23 CN disclosed
US-9359585-B2 Stable nonaqueous reactive skin care and cleansing compositions having a continuous and a discontinuous phase UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) 2016-06-07 US disclosed
US-8986721-B2 Personal care implement containing a stable reactive skin care and cleansing composition UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. (US) 2015-03-24 US disclosed
US-20130118518-A1 Personal Care Implement Containing a Stable Reactive Skin Care and Cleansing Composition CONOPCO, INC., D/B/A UNILEVER (US) 2013-05-16 US disclosed
US-8357383-B2 Personal care implement containing a stable reactive skin care and cleansing composition CONOPCO, INC. (US) 2013-01-22 US disclosed
US-20110014253-A1 PERSONAL CARE IMPLEMENT CONTAINING A STABLE REACTIVE SKIN CARE AND CLEANSING COMPOSITION UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) 2011-01-20 US disclosed
US-7846462-B2 Has a continuous and a discontinuous phase UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) 2010-12-07 US disclosed
US-7344868-B2 Method for synthesizing ceramide-type compounds LASSALLE LAURENT 2008-03-18 US disclosed
US-7344868-B2 Method for synthesizing ceramide-type compounds LASSALLE LAURENT 2008-03-18 US disclosed
EP-1696862-A1 PERSONAL CARE IMPLEMENT CONTAINING A STABLE REACTIVE SKIN CARE AND CLEANSING COMPOSITION Unilever Plc (GB) 2006-09-06 EP disclosed
EP-1691768-A2 STABLE NON-AQUEOUS REACTIVE SKIN CARE AND CLEANSING COMPOSITIONS HAVING A CONTINUOUS AND A DISCONTINUOUS PHASE Unilever Plc (GB) 2006-08-23 EP disclosed
WO-2005063192-A1 PERSONAL CARE IMPLEMENT CONTAINING A STABLE REACTIVE SKIN CARE AND CLEANSING COMPOSITION UNILEVER PLC (GB) 2005-07-14 WO disclosed
WO-2005058271-A2 STABLE NON-AQUEOUS REACTIVE SKIN CARE AND CLEANSING COMPOSITIONS HAVING A CONTINUOUS AND A DISCONTINUOUS PHASE UNILEVER PLC (GB) 2005-06-30 WO disclosed
US-20050136098-A1 Has a continuous and a discontinuous phase UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2005-06-23 US disclosed
US-20050123573-A1 Stable nonaqueous reactive skin care and cleansing compositions having a continuous and a discontinuous phase UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2005-06-09 US disclosed
EP-0702556-B1 (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION UNIV WAKE FOREST (US) 2002-10-23 EP disclosed
US-6030960-A INHIBITING THE PRODUCTION OF HEPATITIS VIRUS-INDUCED ANTIGENS IN A HUMAN SUBJECT BY ADMINISTERING A COMPOUND WAKE FOREST UNIVERSITY (US) 2000-02-29 US disclosed
US-5770584-A ADMINISTERING AN ALKYL LIPID OR ALKYL LIPID DERIVATIVE VIRICIDES WAKE FOREST UNIVERSITY (US) 1998-06-23 US disclosed
US-5762910-A CONTRAST AGENT COMPRISING COMPLEX OF PARAMAGNETIC ION AND COMPOUND BEARING LONG ACYL CHAIN IMARX PHARMACEUTICAL CORP. (US) 1998-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050136098-A1 Has a continuous and a discontinuous phase CUTA, POLR1C, POLQ FAAH 1479/4885ASAH1 807/4885MEN1 4377/4885
US-20110014253-A1 PERSONAL CARE IMPLEMENT CONTAINING A STABLE REACTIVE SKIN CARE AND CLEANSING COMPOSITION CUTA, POLR1C, DSG1 FAAH 2882/4885ASAH1 2417/4885MEN1 4002/4885
US-20050123573-A1 Stable nonaqueous reactive skin care and cleansing compositions having a continuous and a discontinuous phase CUTA, POLR1C, POLQ FAAH 1326/4885ASAH1 919/4885MEN1 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.